The KEYNOTE-028 (NCT02054806) is a multicohort Phase Ib clinical trial that assessed the safety and antitumor activity of pembrolizumab in 26 patients with advanced PD-L1 positive ovarian cancer. This evidence concerns the gene CD274 and ovarian cancer.